Curve Dental vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud dental practice management software offering an all-in-one platform for single offices and growing dental groups. Layton UT; founded 2004; one of the earliest true cloud dental PMS alternatives to legacy Dentrix and Eaglesoft;
About
Curve Dental is a Layton, Utah-based cloud-based dental practice management software company that offers an all-in-one platform combining scheduling, clinical charting, digital imaging, billing, and patient communication in a single browser-based application. Founded in 2004, Curve was among the early movers in cloud dental practice management and has built a platform specifically for independent dental practices and small group practices that want a modern, easy-to-use alternative to legacy on-premise systems like Dentrix and Eaglesoft. Curve's cloud architecture means there is no local server to maintain, no software to install or update, and no data backup to manage—the entire system is accessed through a web browser from any device with an internet connection.\n\nCurve's integrated imaging capability—including digital X-ray sensor compatibility, intraoral camera support, and panoramic image management—is a key differentiator in the cloud practice management market, where many competitors require a separate imaging software. By managing clinical imaging and scheduling in the same platform, Curve eliminates the need to switch between systems during patient appointments and ensures that radiographs are automatically associated with the correct patient chart and treatment records. The platform's clinical charting module supports periodontal charting, treatment planning, electronic prescriptions, and clinical notes in a unified workflow designed for the pace of a busy dental office.\n\nCurve Dental competes with Dentrix Ascend (Henry Schein's cloud offering), Eaglesoft Cloud, Carestream, and Planet DDS's Denticon in the dental practice management market. The company targets single-office practices and small groups of up to 10 locations that want cloud convenience without the enterprise complexity of DSO-focused platforms. Curve differentiates on the all-in-one nature of its platform—imaging included at no additional cost—and the simplicity of its pricing and onboarding experience for practices transitioning from legacy systems.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.